MicroRNAs in renal cell carcinoma: A systematic review of clinical implications (Review)
View/ Open
Author
LI, MING
WANG, YING
SONG, YONGSHENG
BU, RENGE
YIN, BO
FEI, XIANG
GUO, QIZHEN
WU, BIN
Published Version
https://doi.org/10.3892/or.2015.3799Metadata
Show full item recordCitation
LI, MING, YING WANG, YONGSHENG SONG, RENGE BU, BO YIN, XIANG FEI, QIZHEN GUO, and BIN WU. 2015. “MicroRNAs in renal cell carcinoma: A systematic review of clinical implications (Review).” Oncology Reports 33 (4): 1571-1578. doi:10.3892/or.2015.3799. http://dx.doi.org/10.3892/or.2015.3799.Abstract
Despite recent advances in the understanding of the biology of renal cell carcinoma (RCC), successful surgical treatment and implementation of novel-targeted therapies, the prognosis for RCC patients remains poor. Late presentation, tumor heterogeneity and in particular the lack of molecular biomarkers for early detection, classification and the surveillance of RCC treatments are major obstacles. The increasing knowledge regarding the functional role of microRNAs (miRNAs) in pathophysiological processes may provide an important link to the identification of suitable therapeutic targets and diagnostic/prognostic biomarkers for RCC. The aim of this review was to provide new insight into the function of miRNAs in the pathogenesis of RCC and to emphasize their potential as diagnostic and prognostic markers, as well as therapeutic targets.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4358077/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:14351205
Collections
- HMS Scholarly Articles [17917]
Contact administrator regarding this item (to report mistakes or request changes)